EA201391108A1 - Лечение липодистрофии - Google Patents

Лечение липодистрофии

Info

Publication number
EA201391108A1
EA201391108A1 EA201391108A EA201391108A EA201391108A1 EA 201391108 A1 EA201391108 A1 EA 201391108A1 EA 201391108 A EA201391108 A EA 201391108A EA 201391108 A EA201391108 A EA 201391108A EA 201391108 A1 EA201391108 A1 EA 201391108A1
Authority
EA
Eurasian Patent Office
Prior art keywords
hiv
lipodistrophy
treatment
lipohypertrophy
lipoatrophy
Prior art date
Application number
EA201391108A
Other languages
English (en)
Other versions
EA025421B1 (ru
Inventor
Дхирай Гамбхир
Раджендракумар Харипрасад Джани
Бипин Пандей
Каушик Сата
Химаншу Котхари
Панкадж Раманбхаи Пател
Original Assignee
Кадила Хелзкэр Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кадила Хелзкэр Лимитед filed Critical Кадила Хелзкэр Лимитед
Publication of EA201391108A1 publication Critical patent/EA201391108A1/ru
Publication of EA025421B1 publication Critical patent/EA025421B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/333—Radicals substituted by oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Saccharide Compounds (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Ceramic Products (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Настоящее изобретение предлагает терапевтическое соединение формулы (I) и их фармацевтически приемлемые соли для предотвращения и лечения липодистрофии, вызванной в результате инфекции ВИЧ, или для комбинированной терапии ингибиторами протеазы (PI) ВИЧ-1 и/или нуклеозидными ингибиторами обратной транскриптазы (NRTI) путем нейтрализации липогипертрофии, липоатрофии и нарушений обмена веществ у инфицированного ВИЧ пациента.
EA201391108A 2011-01-31 2012-01-30 Лечение липодистрофии EA025421B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN257MU2011 2011-01-31
PCT/IN2012/000069 WO2012104869A1 (en) 2011-01-31 2012-01-30 Treatment for lipodystrophy

Publications (2)

Publication Number Publication Date
EA201391108A1 true EA201391108A1 (ru) 2013-12-30
EA025421B1 EA025421B1 (ru) 2016-12-30

Family

ID=54192841

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391108A EA025421B1 (ru) 2011-01-31 2012-01-30 Лечение липодистрофии

Country Status (29)

Country Link
US (3) US10017470B2 (ru)
EP (2) EP3009136A1 (ru)
JP (2) JP2014504610A (ru)
KR (3) KR20130128451A (ru)
CN (2) CN103354757A (ru)
AP (1) AP3920A (ru)
AU (2) AU2012212992B2 (ru)
BR (1) BR112013019352A2 (ru)
CA (1) CA2825456C (ru)
CL (1) CL2013002166A1 (ru)
CO (1) CO6781497A2 (ru)
CY (1) CY1117564T1 (ru)
DK (1) DK2670486T3 (ru)
EA (1) EA025421B1 (ru)
ES (1) ES2569248T3 (ru)
HR (1) HRP20160403T1 (ru)
HU (1) HUE027512T2 (ru)
IL (2) IL227266B (ru)
ME (1) ME02392B (ru)
MX (1) MX350611B (ru)
MY (1) MY191100A (ru)
NZ (1) NZ612804A (ru)
PL (1) PL2670486T3 (ru)
RS (1) RS54735B1 (ru)
SG (1) SG191772A1 (ru)
SI (1) SI2670486T1 (ru)
SM (1) SMT201600129B (ru)
UA (1) UA110813C2 (ru)
WO (1) WO2012104869A1 (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY191100A (en) 2011-01-31 2022-05-30 Cadila Healthcare Ltd Treatment for lipodystrophy
US9171343B1 (en) 2012-09-11 2015-10-27 Aseko, Inc. Means and method for improved glycemic control for diabetic patients
US9897565B1 (en) 2012-09-11 2018-02-20 Aseko, Inc. System and method for optimizing insulin dosages for diabetic subjects
WO2014174524A1 (en) * 2013-04-22 2014-10-30 Cadila Healthcare Limited A novel composition for nonalcoholic fatty liver disease (nafld)
EP3004053B1 (en) * 2013-05-30 2021-03-24 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201513857A (zh) * 2013-07-05 2015-04-16 Cadila Healthcare Ltd 協同性組成物
IN2013MU02470A (ru) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
US9951009B2 (en) * 2013-08-29 2018-04-24 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof
WO2015033357A2 (en) 2013-09-06 2015-03-12 Cadila Healthcare Limited An improved process for the preparation of pyrrole derivatives
US9486580B2 (en) 2014-01-31 2016-11-08 Aseko, Inc. Insulin management
US9898585B2 (en) 2014-01-31 2018-02-20 Aseko, Inc. Method and system for insulin management
WO2016069475A1 (en) 2014-10-27 2016-05-06 Aseko, Inc. Subcutaneous outpatient management
US11081226B2 (en) 2014-10-27 2021-08-03 Aseko, Inc. Method and controller for administering recommended insulin dosages to a patient
RU2737719C2 (ru) * 2015-02-27 2020-12-02 Ионис Фармасьютикалз, Инк. Модулирование экспрессии аполипопротеина с-iii (аросiii) у пациентов с липодистрофией
JP6858751B2 (ja) 2015-08-20 2021-04-14 アセコー インコーポレイテッド 糖尿病管理療法アドバイザ
WO2017064635A2 (en) 2015-10-14 2017-04-20 Cadila Healthcare Limited Pyrrole compound, compositions and process for preparation thereof
WO2017089980A1 (en) 2015-11-26 2017-06-01 Cadila Healthcare Limited Dual ppar modulators for the treatment of diabetic retinopathy and diabetic eye diseases
WO2017089979A1 (en) 2015-11-26 2017-06-01 Cadila Healthcare Limited Dual ppar modulators for the treatment of diabetic nephropathy and related diseases
JP6840853B2 (ja) 2016-12-09 2021-03-10 カディラ・ヘルスケア・リミテッド 原発性胆汁性胆管炎の治療
US20220071954A1 (en) 2018-12-18 2022-03-10 Cadila Healthcare Limited Saroglitazar for the treatment of hepatocellular carcinoma

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
MX7065E (es) 1980-06-06 1987-04-10 Sankyo Co Un procedimiento microbiologico para preparar derivados de ml-236b
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5089514A (en) 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
RU2134686C1 (ru) 1992-07-03 1999-08-20 Смитклайн Бичам П.Л.С. Гетероциклическое соединение, или его таутомерная форма, и/или фармацевтически приемлемая соль, и/или фармацевтически приемлемый сольват, фармацевтическая композиция, снижающая содержание глюкозы в крови, способ лечения и/или профилактики гипергликемии
GB9225386D0 (en) 1992-12-04 1993-01-27 Smithkline Beecham Plc Novel compounds
US5387613A (en) 1993-07-23 1995-02-07 Ribogene, Inc. Treatment of tachyarrhythmias of supraventricular origin
GB9326171D0 (en) 1993-12-22 1994-02-23 Smithkline Beecham Plc Novel compounds
WO1996004261A1 (en) 1994-07-29 1996-02-15 Smithkline Beecham Plc Benzoxazoles and pryridine derivatives useful in the treatment of the type ii diabetes
ES2164241T3 (es) 1995-04-28 2002-02-16 Daiichi Seiyaku Co Compuestos pentaciclicos.
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
GB9606805D0 (en) 1996-03-30 1996-06-05 Glaxo Wellcome Inc Medicaments
EP0897467B1 (en) 1996-12-24 2003-06-25 Daewoo Motor Co., Ltd. An apparatus with an exhaust gas recirculation valve for an internal combustion engine
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
CN1280574A (zh) 1997-10-27 2001-01-17 雷迪研究基金会 新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物
AU1120599A (en) 1998-04-23 1999-03-08 Dr. Reddy's Research Foundation New heterocyclic compounds and their use in medicine, process for their reparation and pharmaceutical compositions containing them
NZ504106A (en) 1998-05-27 2003-02-28 Dr Fused Oxazine, Thiazine and pipyridine compounds, process for their preparation and pharmaceutical compositions containing them
WO2000023451A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
EP1123292A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
JP2002527503A (ja) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物類、それらの調製及び使用
CO5150173A1 (es) 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
NZ520402A (en) 2000-01-19 2006-04-28 Cadila Healthcare Ltd Novel compounds having hypolipedemic, hypocholesteremic activites, process for their preparation and pharmaceutical compositions containing them
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
WO2002024625A2 (en) 2000-09-22 2002-03-28 Dr. Reddy's Research Foundation Process for the preparation of 3-aryl-2-hydroxy propanoic acid derivatives
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
US6987123B2 (en) 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2005031335A1 (ja) 2003-09-26 2005-04-07 Mitsubishi Rayon Co., Ltd. 電気泳動装置および電気泳動法並びにそれを用いた生体関連物質の検出方法
CN102127053A (zh) 2004-03-15 2011-07-20 武田药品工业株式会社 二肽基肽酶抑制剂
WO2007122635A2 (en) * 2006-04-26 2007-11-01 Astron Research Limited Controlled release formulation comprising anti-epileptic drugs
PT2641596T (pt) 2009-11-26 2018-07-31 Genfit Utilização de derivados de 1,3-difenilprop-2-en-1-ona para tratamento de doenças hepáticas
BR112013008985A2 (pt) 2010-10-12 2016-07-05 Cerecor Inc composições antitussígenas compreendendo memantina
MY191100A (en) 2011-01-31 2022-05-30 Cadila Healthcare Ltd Treatment for lipodystrophy
WO2014174524A1 (en) 2013-04-22 2014-10-30 Cadila Healthcare Limited A novel composition for nonalcoholic fatty liver disease (nafld)
EP3004053B1 (en) 2013-05-30 2021-03-24 Cadila Healthcare Limited A process for preparation of pyrroles having hypolipidemic hypocholesteremic activities
TW201513857A (zh) 2013-07-05 2015-04-16 Cadila Healthcare Ltd 協同性組成物
IN2013MU02470A (ru) 2013-07-25 2015-06-26 Cadila Healthcare Ltd
US9951009B2 (en) 2013-08-29 2018-04-24 Cadila Healthcare Limited Polymorphic form of pyrrole derivative and intermediate thereof
WO2015033357A2 (en) 2013-09-06 2015-03-12 Cadila Healthcare Limited An improved process for the preparation of pyrrole derivatives

Also Published As

Publication number Publication date
US20130338209A1 (en) 2013-12-19
IL227266B (en) 2019-10-31
US9783495B2 (en) 2017-10-10
KR101733414B1 (ko) 2017-05-10
HUE027512T2 (en) 2016-10-28
US10017470B2 (en) 2018-07-10
IL227266A0 (en) 2013-09-30
ES2569248T3 (es) 2016-05-09
JP2014504610A (ja) 2014-02-24
MY191100A (en) 2022-05-30
DK2670486T3 (en) 2016-05-17
SMT201600129B (it) 2016-07-01
IL262611A (en) 2018-12-31
CO6781497A2 (es) 2013-10-31
AU2012212992A1 (en) 2013-07-25
EP2670486B1 (en) 2016-04-06
JP2016028069A (ja) 2016-02-25
MX350611B (es) 2017-09-11
AP3920A (en) 2016-12-02
CA2825456C (en) 2016-01-05
AU2015249076A1 (en) 2015-11-12
CN107056671A (zh) 2017-08-18
CY1117564T1 (el) 2017-04-26
KR20130128451A (ko) 2013-11-26
KR20150100949A (ko) 2015-09-02
SG191772A1 (en) 2013-08-30
US20190100492A1 (en) 2019-04-04
CN103354757A (zh) 2013-10-16
US20170088514A1 (en) 2017-03-30
EA025421B1 (ru) 2016-12-30
AP2013006988A0 (en) 2013-07-31
UA110813C2 (uk) 2016-02-25
ME02392B (me) 2016-09-20
HRP20160403T1 (hr) 2016-06-03
EP3009136A1 (en) 2016-04-20
CA2825456A1 (en) 2012-08-09
CL2013002166A1 (es) 2014-04-11
AU2012212992B2 (en) 2015-11-26
BR112013019352A2 (pt) 2020-07-14
MX2013008012A (es) 2013-08-21
JP5956664B2 (ja) 2016-07-27
PL2670486T3 (pl) 2016-08-31
RS54735B1 (sr) 2016-10-31
SI2670486T1 (sl) 2016-09-30
KR20160038073A (ko) 2016-04-06
EP2670486A1 (en) 2013-12-11
KR101633720B1 (ko) 2016-06-27
NZ612804A (en) 2015-09-25
WO2012104869A1 (en) 2012-08-09

Similar Documents

Publication Publication Date Title
EA201391108A1 (ru) Лечение липодистрофии
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
PH12018502489A1 (en) Antiviral therapy
EA201490254A1 (ru) Комбинированное лечение гепатита с
ECSP13012417A (es) Derivados de ácido napht-2-ilacético para tratar sida
EA201592256A1 (ru) Производные имидазопирролидинона и их применение при лечении заболеваний
EA201591363A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
EA201690687A1 (ru) Ингибиторы репликации вируса иммунодефицита
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
BR112012016673A2 (pt) método de tratamento.
BR112017026061A2 (pt) composto, uso de um composto, e, método de tratamento de uma infecção viral
MX2023014492A (es) Compuestos utiles en la terapia para el vih.
EA202192433A1 (ru) Соединения, полезные в терапии вич
EA201490199A1 (ru) Терапевтические способы
EA201691058A1 (ru) Производные пирролопирролона и их применение для лечения заболеваний
BR112017002449A2 (pt) tratamento de sintomas associados com terapia de privação androgênica
MX2014011520A (es) Administracion de eritoran o sales farmaceuticamente aceptables del mismo para tratar infecciones para ortomixovirus.
EA201491836A1 (ru) Способы лечения рака с использованием ингибитора pi3k и ингибитора mek